Yearly Archives: 2021

Cambium Announces FDA Permission to Begin Two Phase III Studies On Elate Ocular® Biologic for Dry Eye

Studies to Evaluate Standardized, Novel, Enriched Biologic for Ocular Graft-vs.-Host Disease and Moderate to Severe Dry Eye ATLANTA, GA –July 6, 2021 – Cambium Medical Technologies (“Cambium”), a clinical stage company developing novel processed platelets for therapeutic applications, announced today notification from the FDA that the company can begin two Phase III studies on its ...
Read more